W. Rachel Duan

No ORCID on file · 14 papers in corpus · active 2016-2018

Study types

  • article 13
  • rct 1

Condition tags

  • endometriosis 13
  • dysmenorrhea 4
  • chronic_pelvic_pain 2
  • dyspareunia 2
article 2018
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Clinical pharmacology in drug development ·doi:10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…

article 2018
Long-term Effect of Elagolix on Bone Mineral Density in Women with Endometriosis-Associated Pain [38G]
·doi:10.1097/01.aog.0000533387.12236.72

INTRODUCTION: To evaluate the long-term effect of elagolix, an oral, non-peptide GnRH antagonist, on bone mineral density (BMD) in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M, phase 3 studies (12M overall tre…

article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2018
Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]
·doi:10.1097/01.aog.0000533299.54528.7c

INTRODUCTION: Long-term safety and efficacy of elagolix, an oral, non-peptide GnRH antagonist for the management of endometriosis-associated pain, was evaluated in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M,…

article 2017
Long-term effect of elagolix on bone mineral density: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.292
article 2017
Long-term effect of elagolix on the endometrium: results from two phase 3 extension studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2017.07.147
article 2017
Long-Term Effect of Elagolix on the Endometrium: Results from Two Phase 3 Extension Studies in Women with Endometriosis-Associated Pain
·doi:10.1016/j.jmig.2017.08.051
article 2017
Long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain: primary results from two phase 3 extension studies
·doi:10.1016/j.fertnstert.2017.07.293
article 2017
Long-Term Safety and Efficacy of Elagolix Treatment in Women with Endometriosis-Associated Pain: Primary Results From Two Phase 3 Extension Studies
·doi:10.1016/j.jmig.2017.08.078
article 2017
Maintenance of endometriosis-associated pain reduction and quality of life improvement in phase 3 extension studies with elagolix
·doi:10.1016/j.fertnstert.2017.07.294
article 2017
O-GYN-MD-126 Primary Efficacy and Safety Results from Two Double-Blind, Randomized, Placebo-Controlled Studies Of Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, in Women With Endometriosis-Associated Pain
·doi:10.1016/j.jogc.2017.03.067
rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

article 2016
Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.780